1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Peptic Ulcers - Pipeline Review, H1 2016

Peptic Ulcers - Pipeline Review, H1 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 57 pages

Peptic Ulcers - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Peptic Ulcers - Pipeline Review, H1 2016’, provides an overview of the Peptic Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers
- The report reviews pipeline therapeutics for Peptic Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peptic Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Peptic Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peptic Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Peptic Ulcers - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2

Introduction 6
Global Markets Direct Report Coverage 6
Peptic Ulcers Overview 7
Therapeutics Development 8
Pipeline Products for Peptic Ulcers - Overview 8
Peptic Ulcers - Therapeutics under Development by Companies 9
Peptic Ulcers - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Peptic Ulcers - Products under Development by Companies 12
Peptic Ulcers - Companies Involved in Therapeutics Development 13
Ache Laboratorios Farmaceuticos S/A 13
Astellas Pharma Inc. 14
ChoDang Pharm Co., Ltd. 15
Daewoong Pharmaceutical Co., Ltd. 16
Kukje Pharmaceutical Industry Co., Ltd. 17
RaQualia Pharma Inc. 18
Sequella, Inc. 19
Sihuan Pharmaceutical Holdings Group Ltd. 20
Sinil Pharmaceutical Co., Ltd 21
Yooyoung Pharmaceutical Co., Ltd. 22
Peptic Ulcers - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 30
Drug Profiles 31
(ecabet + ranitidine) - Drug Profile 31
Product Description 31
Mechanism Of Action 31
RandD Progress 31
(lansoprazole + omeprazole) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
RandD Progress 32
anaprazole sodium - Drug Profile 33
Product Description 33
Mechanism Of Action 33
RandD Progress 33
ASP-6537 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
RandD Progress 34
DWJ-206 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
RandD Progress 35
KJ-14001 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
RandD Progress 36
PDI-39 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
RandD Progress 37
PMKS-005 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
RandD Progress 38
RQ-00000774 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
RandD Progress 39
SI-001002 SR - Drug Profile 40
Product Description 40
Mechanism Of Action 40
RandD Progress 40
Small Molecule to Inhibit Proton Pump for Peptic Ulcers - Drug Profile 41
Product Description 41
Mechanism Of Action 41
RandD Progress 41
Small Molecules for Gastric Ulcers - Drug Profile 42
Product Description 42
Mechanism Of Action 42
RandD Progress 42
SQ-109 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
RandD Progress 43
YYD-601 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
RandD Progress 47
Peptic Ulcers - Dormant Projects 48
Peptic Ulcers - Discontinued Products 50
Peptic Ulcers - Product Development Milestones 51
Featured News and Press Releases 51
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies 51
Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers 52
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 52
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 53
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy 53
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 54
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) 54
Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court 55
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables
Number of Products under Development for Peptic Ulcers, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Peptic Ulcers - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 13
Peptic Ulcers - Pipeline by Astellas Pharma Inc., H1 2016 14
Peptic Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H1 2016 15
Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 16
Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H1 2016 17
Peptic Ulcers - Pipeline by RaQualia Pharma Inc., H1 2016 18
Peptic Ulcers - Pipeline by Sequella, Inc., H1 2016 19
Peptic Ulcers - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 20
Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016 21
Peptic Ulcers - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Assessment by Combination Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 30
Peptic Ulcers - Dormant Projects, H1 2016 48
Peptic Ulcers - Dormant Projects (Contd..1), H1 2016 49
Peptic Ulcers - Discontinued Products, H1 2016 50

List of Figures
Number of Products under Development for Peptic Ulcers, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Targets, H1 2016 25
Number of Products by Stage and Targets, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 27
Number of Products by Stage and Mechanism of Actions, H1 2016 27
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Stage and Molecule Types, H1 2016 30

Companies Mentioned
Ache Laboratorios Farmaceuticos S/A
Astellas Pharma Inc.
ChoDang Pharm Co., Ltd.
Daewoong Pharmaceutical Co., Ltd.
Kukje Pharmaceutical Industry Co., Ltd.
RaQualia Pharma Inc.
Sequella, Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
Sinil Pharmaceutical Co., Ltd
Yooyoung Pharmaceutical Co., Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Liver Cirrhosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Peptic Ulcer  - Market Insights, Epidemiology and Market Forecast-2023

Peptic Ulcer  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Peptic Ulcer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

Crohn’s disease (CD)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Crohn’s disease (CD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.